Connect Sign In
Ryan Nelson, PharmD, medical director of Precision Medicine at ARUP, was presented with a Double Helix Award by the American Society of Pharmacovigilance (ASP). |
November 15, 2024 |
ARUP Medical Director Ryan Nelson, PharmD, Receives a STRIPE Double Helix Award Ryan Nelson, PharmD, received a Double Helix Award for his work on MetaCensus during the Standardizing |
ARUP Laboratories and Augurex Life Sciences Corp. are partnering to incorporate a 14-3-3η test that will aid in the early detection and management of rheumatoid arthritis. |
October 21, 2024 |
Augurex Announces Agreement With ARUP To Expand Access to Advanced Rheumatoid Arthritis Diagnosis ARUP Laboratories is partnering with Augurex Life Sciences Corp. to include the 14-3-3η test in |
Preeclampsia is characterized by hypertension and one or more signs of physiologic dysfunction and is difficult to diagnose. A new ARUP Consult® topic aims to help clinicians order the right test at the right time. |
September 16, 2024 |
New Preeclampsia Testing Topic on ARUP Consult Includes Information on Angiogenic Biomarkers A new ARUP Consult® topic on testing for preeclampsia, which can be difficult to diagnose, distills |
Digitally colorized transmission electron microscopic image of avian influenza A (H5N1) virus particles (in gold), grown in Madin-Darby canine kidney (MDCK) epithelial cells (in green). |
September 13, 2024 |
ARUP has been awarded a CDC contract for avian influenza A (H5N1) test development, which recognizes our expertise and experience with |
Ryan Nelson, PharmD, ARUP medical director of Precision Medicine, will moderate a session about standards for pharmacogenetic testing at the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Annual Meeting and Consensus Workshop in October. |
August 30, 2024 |
ARUP Medical Director to Moderate Consensus Workshop During STRIPE Annual Meeting Medical Director Ryan Nelson, PharmD, will moderate a STRIPE Annual Meeting workshop in October focused on |
A new test that ARUP offers for preeclampsia risk measures the ratio between two angiogenic factors (sFlt-1 and PlGF) that are produced by the placenta and are involved in the pathophysiology of preeclampsia. |
August 21, 2024 |
First-of-Its-Kind, FDA-Cleared Test Uses Blood-Based Biomarkers To Assess Risk for Preeclampsia A new, first-of-its-kind test uses blood-based biomarkers to assess the risk of developing |
ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine We accelerate groundbreaking diagnostic and prognostic technologies to drive life-changing innovation. Our large, single-site operation and renowned quality framework, combined with our extensive expertise, provide an ideal incubator to advance custom projects for innovative partners. The Sherrie Perkins Research and Innovation Collaboration Grant The Sherrie Perkins Research and Innovation Collaboration Grant funds cutting-edge research in laboratory medicine.
Test Information
